Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections - a Scandinavian real-life study
Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars Normann; Heggelund, Lars; Färkkilä, Martti; Balselv, Ulla; Berlard, Erika; Øvrehus, Anne; Kjær, Mette Skalshøi; Krarup, Henrik; Røge, Birgit Thorup; Hallager, Sofie; Madsen, Lone G; Laursen, Alex Lund; Lagging, Martin; Weis, Nina
Journal article, Peer reviewed
Published version
Permanent lenke
https://hdl.handle.net/10642/7274Utgivelsesdato
2017-07-13Metadata
Vis full innførselSamlinger
Originalversjon
Dalgard, O., Weiland, O., Noraberg, G., Karlsen, L., Heggelund, L., Färkkilâ, M., ... & Krarup, H. (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—a Scandinavian real-life study. PloS one, 12(7), e0179764. https://doi.org/10.1371/journal.pone.0179764Sammendrag
Background and aims
Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia.
Methods
Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included. The fibrosis stage was evaluated by liver biopsy or transient liver elastography. The following treatments were given according availability and local guidelines: 1) SOF + ribavirin (RBV) for 24 weeks, 2) SOF + daclatasvir (DCV) +/-RBV for 12–24 weeks, 3) SOF + pegylated interferon alpha (peg-IFN-α) + RBV for 12 weeks or 4) SOF/ledipasvir (LDV) + RBV for 12–16 weeks. The primary endpoint was sustained virological response (SVR) assessed at week 12 (SVR12) after end of treatment.
Results
We included 316 patients with a mean age of 55 years (range 24–79), 70% men, 49% treatment experienced, 58% with compensated cirrhosis and 12% with decompensated cirrhosis.In the modified intention to treat (mITT) population SVR12 was achieved in 284/311 (91%) patients. Among 26 treatment failures, five had non-response, 3 breakthrough and 18 relapse. Five patients were not included in the mITT population. Three patients died from reasons unrelated to treatment and two were lost to follow-up. The SVR12 rate was similar for all treatment regimens, but lower in men (p = 0.042), and in patients with decompensated liver disease (p = 0.004).
Conclusion
We found that sofosbuvir based treatment in a real-life setting could offer SVR rates exceeding 90% in patients with HCV genotype 3 infection and advanced liver disease.